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infusions), which avoids exposing 
patients who are immunosuppressed 
to high-risk procedures, and reduces 
the burden on the health-care system 
(particularly intensive care units), which 
are under severe pressure because 
of the high number of patients with 
COVID-19 who need treatment. If the 
procedure cannot be postponed, cancer 
centres in regions that are not affected 
(or are affected to a lesser extent) by 
COVID-19 should be identified and 
patients should be transferred. This 
option has been implemented in 
the Lombardy region of Italy. Rapid 
diagnosis of patients suspected of 
having COVID-19 should also be 
pursued. A report5 shows that 86% 
of people infected with SARS-CoV-2 
remain undiagnosed, and this needs 
to be taken into account. Countries 
such as South Korea, Hong Kong, and 
Singapore implemented extensive 
testing from the early phase of the 
COVID-19 epidemic, which proved to 
be effective in controlling the spread 
of infection. This action preserved the 
function of their health-care systems. 
We can observe this difference from the 
lower case fatality rate of SARS-CoV-2 
in South Korea than in Italy and Spain: 
1% in South Korea, 8% in Italy, and 
4% in Spain as of March 17, 2020. 
For patients with cancer who do not 
need such intensive therapies, home-
care options should be considered, 
such as telemedicine and mobile 
health-care devices. Moreover, 
remote monitoring could be a good 
option for follow-up for patients 
with COVID-19 who do not require 
hospitalisation. Close collaboration of 
the treating physician with infectious 
disease consultants is of paramount 
importance in this setting.
Considering the issues we are 
encountering in our countries, we 
advise the oncological international 
community to plan effective strategies 
in advance to protect this very specific 
category of patients who need life-
saving therapies and who could be 
severely affected by SARS-CoV-2 
infection.
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Adjusting for possible imbalances 
with respect to the minimisation 
factors, the differences for all three 
endpoints remain significant: 
freedom from immunosuppressive 
therapy (OR 4·60, 95% CI 1·97–10·75; 
p=0·0042); time to chronic GVHD 
(HR 0·55, 0·32–0·95; p=0·031); and 
overall survival (HR 0·49, 0·29–0·83; 
p=0·0080).
These results are very similar to our 
published findings and support our 
assertion that random assignment 
to receive anti-thymocyte globulin 
was the most important factor in 
influencing the favourable results.1 
We believe that the improved overall 
survival of patients treated with anti-
thymocyte globulin was because of 
the specific dose and schedule of anti-
thymocyte globulin given in our trial. 
The regimen we used was adapted 
from a case-control study2 in which a 
survival advantage for patients treated 
with anti-thymocyte globulin had been 
shown. In addition, a simulation study3 
found that this regimen resulted in a 
higher proportion of patients receiving 
an optimal exposure to anti-thymocyte 
globulin than two other recommended 
regimens. Nevertheless, as Admiraal 
and colleagues3 have shown, there is 
room for improvment so that even 
better schedules of anti-thymocyte 
globulin might be advised in future.
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Handling the COVID-19 
pandemic in the 
oncological setting
We read with interest the Health 
Policy piece1 by Remuzzi and Remuzzi 
regarding the COVID-19 epidemic 
in Italy. Italy is showing us how a 
developed country that has never 
tackled such a health-care problem in 
the last hundred years is handling this 
viral outbreak.
History shows us how epidemics 
have unfolded in similar ways.2 
However, several factors have changed 
in the past twenty years. For example, 
the Internet now helps us share 
information between health-care 
communities in real time, and social 
media can positively affect the public, 
by educating people and neutralising 
fake news. Additionally, personalised 
medicine can now be applied to 
epidemics. SARS-CoV-2 affects 
older patients and those who are 
immunosuppressed particularly badly.3 
Patients with cancer are an example 
of how considering all people equal 
before epidemics could negatively 
affect those who are frail. In a report4 
from Liang and colleagues, patients 
with cancer living in China had 
worse outcomes following infection 
with SARS-CoV-2 than the general 
population.
How can we protect the specific 
category of patients who require 
life-saving therapies to treat cancer? 
We suggest postponing all high-
risk procedures that can be delayed 
(eg, chimeric antigen receptor T-cell 
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